Prognóstico de tumores testiculares germinativos
| Autor: | Antonio Carlos Pereira Martins, Adauto José Cologna, José Anastácio Dias Neto, Cassio Botene Schneider, André Luiz Alonso Domingos, Silvio Tucci, Haylton Jorge Suaid |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
Disease specific
medicine.medical_specialty não seminoma endocrine system diseases RD1-811 medicine.medical_treatment lcsh:Surgery Testicular Germ Cell Tumor tumor germinativo Stage ii urologic and male genital diseases Gastroenterology Internal medicine medicine Risk factor Survival analysis Chemotherapy business.industry seminoma lcsh:RD1-811 Seminoma medicine.disease tumor testicular Lymphadenectomy Surgery business |
| Zdroj: | Acta Cirurgica Brasileira, Vol 17, Iss suppl 3, Pp 55-58 (2002) Acta Cirurgica Brasileira, Vol 17, Iss suppl.3, Pp 55-58 (2002) Acta Cirúrgica Brasileira v.17 suppl.3 2002 Acta Cirúrgica Brasileira Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC) instacron:SBDPC |
| ISSN: | 0102-8650 |
| Popis: | OBJECTIVE: The aim of the study is to analyze the characteristics and the evolution of patients with testicular germ cell tumors. METHODS: We analyzed 29 patients: 14 seminomas and 15 non-seminomas. All of them underwent orquiectomy. Patients with seminomas stage II and III received adjuvant treatment with raditherapy, and those with non-seminomas stage II and III received neoadjuvant chemotherapy followed by lymphadenectomy. Mean followup for seminomas was 56 months and for non-seminomas it was 40 months. RESULTS: The most common complain was an increase in testis volume (57%) and pain (30%). The mean age in seminomas was 41.2 years and in non-seminomas it was 29.2 years. Previous criptorquidy was refered by 28.5% of patients with seminomas and 15.5% with non-seminomas. The respective proportions of stages I, II and III were 79%, 14% and 7% in seminomas, and 40%, 27% and 33% in non-seminomas. Patients with seminomas did not show serum rise of alfa-fetoprotein or b-HCG while those with non-seminomas such tumor markes were elevated respectively in 46.6% and 33.3% of the sample. Disease specific death occurred in 1 patient with seminoma and in 3 with non-seminoma tumor, but survival curves were similar for both groups. CONCLUSION: In spite of the earlier treatment of criptorquidy such an antecedent stand as an important risk factor for the development of testicular germ cell tumor. Even though non-seminomas presents with higher stages the survival curves are similar for both groups of tumors. Analyze 29 patients that were submitted to orquiectomy (14 seminomas e 15 non seminomas), concerning their age, signs and symptoms, risk factors, clinical staging, tumor markers follow up and survival rates. RESULTS: There was no statistically difference in survival rates of patients with seminomas and non-seminomas tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|